The GLP 1 Effect: From Medical Trend to Dental Risk
Author: Julie Goldberg, DDS, Professional Dental Risk Specialist at PMIG
GLP 1
receptor agonists, commonly prescribed for type 2 diabetes and weight
management, are now encountered routinely in dental practice. While not dental
medications, GLP 1s introduce emerging professional liability exposures; these
exposures extend beyond sedation and anesthesia to include xerostomia, caries
progression, periodontal concerns, treatment planning complications, and
potential informed consent gaps. This article will explore how a failure to
account for GLP-1 medication effects may be cited in malpractice allegations
and will offer strategies to mitigate the likelihood of such allegations.
Sedation
and Procedural Risks
GLP 1
receptor agonists are associated with delayed gastric emptying, increasing the
risk of:
- Residual gastric contents despite fasting
- Regurgitation and aspiration
- Nausea and vomiting during procedures
These risks
are most relevant for patients undergoing:
- IV sedation
- Oral sedation
- General anesthesia
- Lengthy or invasive dental procedures
Aspiration
events, while uncommon, are high severity claims with substantial exposure.
- Post event allegations commonly include:
- Failure to identify GLP 1 use
- Proceeding with sedation despite increased aspiration risk
- Inadequate informed consent
- Deviation from accepted safety practices
Oral
Health–Related Risks
GLP 1 use has
also been associated with side effects that directly affect dental outcomes,
including:
- Xerostomia (dry mouth)
- Dietary pattern changes
- Enamel erosion secondary to nausea
- Increased caries and periodontal risk
When these
factors are not identified, documented, and addressed, dentists may face
allegations of:
- failure to diagnose,
- failure to warn, or
- failure to modify care despite identifiable risk factors.
Risk
Management Strategies
1. Improve Medical History Processes
- Update intake forms to specifically ask about injectable and weight loss medications
- Train staff to flag GLP 1 drugs
- Reconfirm medications prior to sedation or major procedures
2. Identify and Manage Xerostomia
- Assess salivary flow during examinations
- Document findings and patient counseling
- Adjust preventive plans (fluoride, recalls, saliva support)
3. Individualize Sedation Decisions
- Account for GLP 1 use when selecting sedation type and timing
- Use caution during early therapy or dose escalation
- Delay elective sedation when risk assessment is unclear
4. Strengthen Informed Consent
- Discuss medication specific risks when relevant
- Document patient understanding and questions
5. Coordinate Care and Document Reasoning
- Communicate with prescribing clinicians when medication issues affect care
- Document clinical rationale when proceeding, modifying, or postponing treatment
- Maintain flexible protocols that allow individualized judgment
GLP 1
receptor agonists represent a multifaceted and evolving professional liability
exposure for dental practices. Practices that proactively identify medication
use, assess oral side effects, individualize care decisions, and document
clinical reasoning are best positioned to reduce claim exposure and enhance
defensibility.
For questions related to dental risk management, contact Dr. Julie Goldberg, Senior Dental Risk Specialist with PM Dental Protect, PMIC. julie.goldberg@phmic.com.
This information is intended to provide general
information only on specific risk management topics. It is not intended to
provide coverage determinations or coverage positions, nor is it to be
construed as legal, medical, or professional advice in any form whatsoever.
